Drug Profile
Research programme: anti-cancer therapeutics - Celgene Corporation/ Cancer Research Technology
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Celgene Corporation
- Class Antineoplastics
- Mechanism of Action Peptide biosynthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for research development in Cancer in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 15 Dec 2017 Cancer Research Technology and Celgene Corporation agree to co-promote and co-develop anti-cancer therapeutics for Cancer